Pharmaco-Kinesis Corporation Develops First Nanodrug Combination for Glioma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaco-Kinesis Corporation Develops First Nanodrug Combination for Glioma



Pharmaco-Kinesis Corporation (PKC) announced that it is developing the first nanodrug combination of Merck’s temozolomide and Celgene’s thalidomide (in a 50:50 ratio) for the treatment of gliomas and other cancers. PKC will collaborate with the University of California, San Diego’s department of nano-engineering at the Moores cancer centre to develop the nanodroplet formulation.

According to PKC, 2000 to 20000 molecules of each type of drug can be packaged in one nanodroplet. Preliminary studies have indicated that the ratio of these different drugs can be precisely controlled. PKC’s goal is to produce nanodroplets that have special affinities for cancer cells with enhanced efficacy in destroying such cells compared with conventional chemotherapy.

PKC has begun in vivo testing of the temozolomide–thalidomide nanodroplets. Preliminary findings show that the combination is significantly more effective than the current commercially available formulations of these drugs that are being used in the clinic.

It is thought that direct local delivery is necessary to achieve the potentially high efficacy of the nanodrugs. PKC is developing a microminiaturized metronomic biofeedback pump nano (MBPn) version, a fully implantable infusion pump that enables programmable, metronomic, local delivery and sampling via a multichannel catheter that has the potential to avoid elimination by the liver. The company hopes that the MBPn will enhance anticancer activity of the drugs at the target site while reducing adverse effects on healthy cells.

"We are conducting ongoing development and testing in order to prove the efficacy of delivering proprietary nanodroplet formulations of anticancer medications using our MBP," said Frank Adell, CEO of PKC in a press statement. "If these tests are successful, we believe PKC will produce a major advance in treating gliomas and potentially other types of cancer as well."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here